Vaginal Vault Prolapse Surgery in India and UAE | Complete Patient Guide

• Confirmed vaginal vault prolapse at POP-Q Stage II or higher with symptomatic vaginal bulge, pressure, or pelvic heaviness

• Prior hysterectomy (any route: abdominal, laparoscopic, or vaginal) with subsequent apical descent

• Failure or recurrence after previous native-tissue vault repair (sacrospinous fixation, McCall culdoplasty, high uterosacral suspension)

• Concurrent multi-compartment prolapse (anterior cystocele, posterior rectocele, or perineal descent) requiring combined repair

• Patients with stress urinary incontinence unmasked on urodynamics after prolapse reduction — eligible for concurrent mid-urethral sling (TVT/TOT)

• Pre-operative diagnostics required: full POP-Q examination, multichannel urodynamic studies (filling cystometry, pressure-flow study, leak-point pressure), pelvic floor ultrasound or dynamic MRI defecography (for enterocele/rectocele delineation), routine blood panel (CBC, CMP, coagulation screen, HbA1c in diabetics), ECG and anaesthesia-fitness assessment

• Contraindications — Absolute: active pelvic sepsis or unresolved pelvic inflammatory disease; uncontrolled coagulopathy not correctable pre-operatively; untreated malignancy of the pelvic viscera

• Contraindications — Relative: morbid obesity (BMI >40, increases mesh-related complications and anaesthetic risk — weight optimisation preferred before surgery); severe cardiopulmonary disease (ASA Class IV — thorough anaesthesia review and risk-benefit discussion required); prior extensive pelvic radiation (raises risk of mesh erosion and wound dehiscence — native-tissue or biologic graft repair preferred); active mesh complications from prior pelvic floor surgery (mesh erosion, chronic pelvic pain, dyspareunia)

• Patients on anticoagulation (warfarin, DOACs) or dual antiplatelet therapy require bridging protocols per local haematology guidelines

• Age alone is not a contraindication; frailty scoring (Clinical Frailty Scale, Fried criteria) guides operative risk stratification in patients over 70

Vaginal vault prolapse repair encompasses both native-tissue and mesh-augmented approaches, delivered via vaginal, open abdominal, laparoscopic, or robotic platforms. The optimal technique is individualised based on POP-Q stage, compartment involvement, prior surgeries, patient fitness, and surgeon expertise.

1. Abdominal Sacrocolpopexy (Open ASC)

The historical gold standard. The vaginal apex is suspended to the anterior longitudinal ligament at the sacral promontory (S1–S2) using a Y-shaped polypropylene mesh bridge. Long-term objective cure rates: 78–92% at 5 years. Preferred in patients requiring concurrent abdominal procedures (e.g., Burch colposuspension for stress incontinence, bowel surgery for rectovaginal fistula). Disadvantages: longer hospitalisation (4–6 days), higher blood loss, extended recovery.

2. Laparoscopic Sacrocolpopexy (LSC)

Replicates the open technique via four to five laparoscopic ports. Provides equivalent anatomical correction with reduced blood loss, shorter hospital stay (2–3 days), and faster return to activity. Requires advanced laparoscopic training. Success rates: 80–90% at 5 years.

3. Robotic-Assisted Sacrocolpopexy (RASC) — using the da Vinci Xi or SP System

Robotic platforms provide 10× magnification, 7-degree-of-freedom articulated instruments, and tremor filtration, enabling precise mesh attachment and suturing in the confined retropubic and presacral spaces. RASC is particularly advantageous in patients with obesity, prior abdominal surgeries, or complex multi-compartment prolapse requiring concurrent bladder-neck suspension. Operative time is longer than LSC, but surgical precision and learning-curve acceleration are superior. The PROSPER RCT and several large cohort studies show equivalent or superior anatomical outcomes versus open ASC, with shorter recovery.

4. Sacrospinous Ligament Fixation (SSLF) — Vaginal Native-Tissue Approach

The vaginal apex is sutured (permanent or delayed-absorbable sutures, e.g., PDS II or Ethibond) to the sacrospinous ligament, typically right-sided, via a posterior vaginal incision. Performed vaginally under regional or general anaesthesia. Success rate approximately 67–75% at 5 years (inferior to sacrocolpopexy but still effective, especially for less advanced prolapse or medically frail patients unable to tolerate abdominal surgery). Risk of buttock/sciatic pain (1–3%), haemorrhage from inferior gluteal vessels (0.5%), and suture erosion.

5. Uterosacral Ligament Suspension (ULS) — High Vaginal Approach

Apical suspension using permanent sutures placed at the level of the ischial spines in the uterosacral ligaments. Can be performed vaginally or laparoscopically. Ureteral kinking is the principal complication (risk 1–11%); intra-operative cystoscopy is mandatory to confirm bilateral ureteral patency. Long-term cure: 68–80%.

6. Hysteropexy (Uterine-Sparing Repair for patients with uterovaginal prolapse who have not yet had hysterectomy)

Although vault prolapse by definition is post-hysterectomy, patients presenting with uterovaginal prolapse wishing uterine preservation may undergo laparoscopic or robotic sacrohysteropexy (mesh from uterine isthmus to sacrum), avoiding hysterectomy with equivalent apical outcomes.

7. Obliterative Procedures — Colpocleisis (LeFort or Total)

Reserved for elderly, medically frail, sexually inactive patients who desire definitive prolapse resolution. The vaginal canal is partially or completely closed, preventing vault re-descent. Carries very high success rates (>95%) but results in permanent loss of penetrative sexual function. Decision must be made with informed consent following detailed counselling.

8. Concurrent Procedures — Frequently Combined at the Same Setting

• Mid-urethral sling (tension-free vaginal tape [TVT] or transobturator tape [TOT]) for co-existing or occult stress urinary incontinence

• Anterior colporrhaphy for cystocele repair

• Posterior colporrhaphy and perineorrhaphy for rectocele/perineal defects

• Enterocele repair (high peritoneal closure)

Technology Highlights: Robotic platforms (da Vinci Xi), ultrasound-guided suture placement, 3D laparoscopy, barbed suture technology (V-Loc, Stratafix) for mesh fixation, and fluorescence imaging (Firefly mode in robotic systems) for ureteral visualisation are available at leading centres in both India and the UAE.

Pre-Operative Phase (4–6 weeks before surgery):

• GAF Healthcare coordinates remote consultation with the chosen urogynecologist; surgical records, prior operative reports, and imaging are reviewed

• Urodynamic studies and dynamic pelvic MRI or ultrasound performed either at home country or on arrival

• Anaesthesia pre-assessment (ECG, echo if indicated, blood work, DVT risk scoring using Caprini Score)

• Medications adjusted: anticoagulants bridged per haematology protocol; oestrogen pessary prescribed for 4–6 weeks pre-operatively to improve vaginal tissue quality in postmenopausal patients

• Bowel preparation: low-residue diet 48 hours pre-op; mechanical bowel prep if concurrent colorectal procedure planned

• Pelvic floor physiotherapy assessment for baseline documentation and post-op planning

Day of Admission (Day 0):

• Admission 12–24 hours before surgery (or morning of surgery for low-risk cases)

• Consent process, anaesthesia review, antibiotic prophylaxis (cefazolin 2g IV or vancomycin for penicillin-allergic patients per ACOG guidelines)

• Sequential compression devices and LMWH (enoxaparin or dalteparin) initiated for DVT prophylaxis

• General or regional (spinal/epidural combined) anaesthesia administered

Surgery (Day 0 — Duration 2–4 hours depending on approach and concurrent procedures):

• Minimally invasive (laparoscopic or robotic): 2–4 ports placed; mesh positioned and fixed to vaginal apex and sacral promontory under direct vision; cystoscopy performed to confirm ureteral integrity

• Open sacrocolpopexy: midline or Pfannenstiel incision; mesh fixed as above

• Vaginal approach (SSLF/ULS): sutures placed under direct vaginal exposure; intra-operative cystoscopy mandatory

• Concurrent repairs completed in the same operative setting

• Bladder catheter (Foley) left in situ

Immediate Post-Operative (Days 1–2):

• Monitored in surgical ward; IV analgesia (multimodal: paracetamol, NSAIDs, low-dose opioid PRN)

• Early ambulation within 6–12 hours post-op (critical for DVT prevention)

• Urethral catheter removed at 24–48 hours; trial of void performed; bladder scan to confirm post-void residual <100 mL

• Liquid diet advancing to soft diet by Day 1

• VTE prophylaxis continued with LMWH

Hospital Discharge (Days 2–4 for minimally invasive; Days 4–6 for open):

• Discharge criteria: independent ambulation, pain controlled on oral analgesia, normal voiding, no fever, wound satisfactory

• Written discharge instructions: no lifting >5 kg for 6 weeks, pelvic rest (no intercourse, tampons, or vaginal douching) for 8–12 weeks

• Oral antibiotics for 5–7 days if indicated; continuation of LMWH for 14–28 days post-discharge

Post-Operative Recovery Milestones:

• Week 1–2: Rest, light indoor walking, catheter removed if still in situ; wound inspection

• Week 2–3: Outpatient review with surgeon; removal of skin clips or sutures if used; urodynamic assessment if voiding difficulties persist

• Week 3–4 (Minimally Invasive): Cleared for long-haul international flight after DVT-risk assessment (adequate hydration, compression stockings, in-flight ambulation advised); pain should be minimal

• Week 5–6 (Open Approach): Cleared for international travel after confirming wound healing and normal voiding

• Week 6: Return to light office-based work; pelvic floor physiotherapy commenced

• Week 8–12: Resumption of sexual activity if mucosa healed (confirmed on examination)

• Week 12 and 6 months: Remote follow-up with GAF Healthcare-coordinated telemedicine appointments with the operating surgeon; POP-Q re-assessment at 6 months to document anatomical outcome